Please use this identifier to cite or link to this item: https://doi.org/10.1212/WNL.0000000000001953
Title: Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants
Authors: Oosterveld L.P.
Allen J.C.
Ng E.Y.L.
Seah S.-H.
Tay K.-Y.
Au W.-L. 
Tan E.-K. 
Tan L.C.S.
Issue Date: 2015
Publisher: Lippincott Williams and Wilkins
Citation: Oosterveld L.P., Allen J.C., Ng E.Y.L., Seah S.-H., Tay K.-Y., Au W.-L., Tan E.-K., Tan L.C.S. (2015). Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants. Neurology 85 (12) : 1039-1042. ScholarBank@NUS Repository. https://doi.org/10.1212/WNL.0000000000001953
Abstract: Objectives: In a longitudinal follow-up study, we compared the clinical features and motor progression of patients with Parkinson disease (PD) who are carriers of the leucine-rich repeat kinase 2 (LRRK2) gene risk variants with patients who are noncarriers. Methods: We prospectively evaluated a cohort of patients with PD for their clinical characteristics, disease severity, and LRRK2 genotype. Carriers of risk variants (G2385R, R1628P, S1647T) and noncarriers were classified separately. A longitudinal, linear mixed model analysis of motor score progression was performed to compare motor progression between the 2 groups. Motor score progression was defined as the difference between Unified Parkinson's Disease Rating Scale motor score at baseline and follow-up scores. Results: A total of 184 patients (122 risk variant carriers and 62 noncarriers) were evaluated and followed up for up to 6.5 years. No differences in demographics and baseline disease characteristics were found. In the longitudinal, linear mixed model analysis, risk variant carriers experienced greater rate of motor progression than noncarriers after 4 years from the date of diagnosis (p ? 0.018). Conclusions: PD LRRK2 risk variant carriers showed greater motor progression after 4 years of disease duration compared with noncarrier patients, suggesting that these risk variants may facilitate neurodegeneration with increasing disease duration. � 2015 American Academy of Neurology.
Source Title: Neurology
URI: http://scholarbank.nus.edu.sg/handle/10635/149105
ISSN: 0028-3878
DOI: 10.1212/WNL.0000000000001953
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

14
checked on Jan 16, 2020

WEB OF SCIENCETM
Citations

12
checked on Jul 17, 2019

Page view(s)

79
checked on Jan 17, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.